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Abstract
Background: The issue of endocrine disrupting chemicals (EDCs) is receiving wide attention from both the scientific
and regulatory communities. Recent analyses of the EDC literature have been criticized for failing to use transparent
and objective approaches to draw conclusions about the strength of evidence linking EDC exposures to adverse health
or environmental outcomes. Systematic review methodologies are ideal for addressing this issue as they provide
transparent and consistent approaches to study selection and evaluation. Objective methods are needed for
integrating the multiple streams of evidence (epidemiology, wildlife, laboratory animal, in vitro, and in silico data)
that are relevant in assessing EDCs.
Methods: We have developed a framework for the systematic review and integrated assessment (SYRINA) of EDC
studies. The framework was designed for use with the International Program on Chemical Safety (IPCS) and World
Health Organization (WHO) definition of an EDC, which requires appraisal of evidence regarding 1) association
between exposure and an adverse effect, 2) association between exposure and endocrine disrupting activity, and
3) a plausible link between the adverse effect and the endocrine disrupting activity.
Results: Building from existing methodologies for evaluating and synthesizing evidence, the SYRINA framework
includes seven steps: 1) Formulate the problem; 2) Develop the review protocol; 3) Identify relevant evidence; 4)
Evaluate evidence from individual studies; 5) Summarize and evaluate each stream of evidence; 6) Integrate evidence
across all streams; 7) Draw conclusions, make recommendations, and evaluate uncertainties. The proposed method is
tailored to the IPCS/WHO definition of an EDC but offers flexibility for use in the context of other definitions of EDCs.
Conclusions: When using the SYRINA framework, the overall objective is to provide the evidence base needed to
support decision making, including any action to avoid/minimise potential adverse effects of exposures. This framework
allows for the evaluation and synthesis of evidence from multiple evidence streams. Finally, a decision regarding
regulatory action is not only dependent on the strength of evidence, but also the consequences of action/inaction, e.g.
limited or weak evidence may be sufficient to justify action if consequences are serious or irreversible.
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evidence, Adverse effect, Endocrine disrupting activity, Evidence integration, Epidemiology, In vivo
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Background
Endocrine disrupting chemicals (EDCs) have received
significant attention by scientists across numerous disci-
plines and risk assessors since the term was first coined
in the 1990s [1–5]. Concerns have been raised about as-
sociations between EDC exposures and human diseases
[6–8], particularly as non-communicable disease rates
have risen for many diseases with an endocrine basis [9].
Similarly, studies conducted in laboratory animals indi-
cate that EDC exposures can induce outcomes related to
many of these same diseases [3, 10–13].
Since the term ‘endocrine disruptor’ was first used, nu-
merous definitions have been proposed by various
groups and agencies. The 2002 report by the Inter-
national Programme on Chemical Safety and World
Health Organization (IPCS/WHO) defined an EDC as
“an exogenous substance or mixture that alters func-
tion(s) of the endocrine system and consequently causes
adverse effects in an intact organism, or its progeny, or
(sub)populations” [14]. This definition was used again in
the 2012 State of Science on EDCs published by the UN
Environment Programme (UNEP) and WHO [15]. Using
the major components of the IPCS/WHO and the
UNEP/WHO definition of an EDC, identifying a com-
pound as an EDC therefore requires appraisal of:
(1)evidence of an (adverse) effect, (remembering that
reversible effects might be adverse, there can be a
continuum of effects from “initiating events” to
“apical effects” induced by the chemical, and that
there remains a debate about what should be
considered “adverse” outcomes [12, 16, 17])
(2)evidence of endocrine disrupting activity
(remembering that endocrine disrupting activity
extends beyond ‘endocrine active’ compounds and
includes disruption to hormone binding, synthesis,
secretion, transport and metabolism)
(3)evidence of a plausible link between the observed
adverse effect and the endocrine disrupting activity
We have focused on the IPCS/WHO definition in this
manuscript for a number of reasons. First, the use of this
definition by the WHO and other international organi-
zations suggests that it is relevant across the globe. Sec-
ond, this definition provides a framework for testing, as
it is the strictest definition requiring detailed data to ad-
dress specific points. As discussed later in this manu-
script, the selection of other definitions for an EDC may
be appropriate in specific contexts, and we provide sug-
gestions for how a decision-making framework would be
adapted for these definitions.
Numerous recent reports have summarized the ‘state
of the science’ on EDCs [3, 12, 18–22]. These include
a 2011 State-of-the-Art Report to the European
Commission (SAREC) on EDCs [19] and a report pub-
lished in February 2013 by UNEP/WHO, entitled
“State of the Science of Endocrine Disrupting Chemi-
cals – 2012” [15] which was an update of the IPCS/
WHO 2002 report, “Global Assessment of the State of-
the-Science of Endocrine Disruptors” [23]. Using the
available evidence, the 2013 UNEP/WHO report [15]
drew several key conclusions including: 1) Laboratory
studies support the hypothesis that chemical expo-
sures contribute to endocrine disorders in humans
and wildlife; 2) Wildlife populations have been af-
fected by endocrine disruption, with negative impacts
on growth and reproduction; 3) Internationally agreed and
validated test methods for the identification of endocrine
disruptors (sometimes called guideline endpoints) capture
only a limited range of the known spectrum of endocrine
disrupting effects. As a result harmful effects in humans
and wildlife may be overlooked; and 4) Disease risk due to
EDCs may be significantly underestimated.
A need for systematic review and integrative
assessment criteria
In the 2013 UNEP/WHO report on EDCs [15], the au-
thors discussed the need to develop a structured frame-
work for evaluating evidence of EDC effects, stating
“There is currently no widely agreed system for evaluat-
ing the strength of evidence of associations between expo-
sures to chemicals (including EDCs) and adverse health
outcomes. The need for developing better approaches for
evaluating the strength of evidence, together with im-
proved methods of risk assessment, is widely recognized.
Methods for synthesizing the science into evidence-based
decisions have been developed and validated in clinical
arenas. However, due to differences between environmen-
tal and clinical health sciences, the evidence base and
decision context of these methods are not applicable to
exposures to environmental contaminants, including
EDCs.” Here, we present adaptations to the systematic
review approach which do make them applicable in this
context.
The term “systematic review” refers to an approach
that uses pre-established, consistent and transparent
methods to identify and evaluate all available research
and information relevant to a research question, topic,
or phenomenon [24–28]. The primary goal of systematic
reviews is to use transparent, valid and systematically ap-
plied criteria to reduce the influence of reviewer bias (in
both study selection and study evaluation) and error in
the evaluation process [29, 30]. Here, the term ‘transpar-
ent’ refers to the open disclosure of the methods to be
used, but it is also important to note that ‘transparency’
refers to all aspects of a systematic review, from how the
problem statement is formulated, to how the literature is
searched, to how data are evaluated and reported. The
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purpose of systematically evaluating the methodological
quality of individual studies is to reliably distinguish
along a continuum those that are better and more dir-
ectly informative from those that are weaker and less
directly informative. Systematic reviews follow a set
protocol, and though there may be differences in these
protocols both within and across fields, they typically in-
clude the same key elements (Table 1).
Although the use of objective and systematic review
methods for identifying, evaluating and integrating evi-
dence is widely accepted in carcinogen hazard evaluation
[31], adaptation of methods used in the clinical sciences
to other endpoints – including the analysis of EDCs –
has only recently started [27, 29, 32]. The need for such
analytical tools has been recognized with new methods
that have been developed by academic scientists (e.g. the
Navigation Guide [29, 30] and SciRAP [33]) as well as
the International Agency for Research on Cancer (IARC)
and its collaborating experts [34], the European Food
Safety Authority (EFSA) and the US National Toxicology
Program (e.g. Office of Health Assessment and Transla-
tion, OHAT, and the Office of the Report on Carcino-
gens, ORoC) [28, 35–37]. Detailed descriptions of the
development of systematic reviews in the field of envir-
onmental health sciences have been provided elsewhere
[29, 30, 35, 36, 38, 39].
Systematic review approaches are promoted in regula-
tory hazard and risk assessment of chemicals in the EU,
although guidance for how to conduct such reviews is
very limited or even lacking for many groups of chemi-
cals [40]. This lack of guidance potentially hampers con-
sistent and transparent use of systematic review in the
risk assessment of chemicals.
One challenge in developing and implementing sys-
tematic review methods for EDCs is that information is
derived from all levels of investigation – including bio-
chemical and cell-based research, studies of mechanisms
and adverse effects in laboratory animals, epidemio-
logical studies and exposure science [41]. (Note that
throughout the text, we refer to these broad study
designs [epidemiology, laboratory animal, etc.] as differ-
ent ‘data streams’ or ‘evidence streams’.) Furthermore,
the evidence required to conclude that a compound is
an EDC, according to the IPCS/WHO definition, re-
quires multiple steps: the chemical must induce an ad-
verse effect and there must be a plausible link between
that adverse effect and endocrine disrupting activity.
Building upon the available systematic review methods
in environmental health sciences and adapting them for
use specifically for EDCs would expand and improve our
capacity to document the strength of the evidence link-
ing EDC exposures and health outcomes. Improved
methodologies could also advance research and decision
making by shedding light on where the data are suffi-
ciently strong to inform policy decisions and where new
data are needed.
In Section III we present a framework for the system-
atic review of EDC studies. The framework we have de-
veloped can be used to identify substances as EDCs
according to the IPCS/WHO definition. This process
also assesses the strength of evidence associating an
EDC with a health or environmental outcome. Each
stream of evidence (mechanistic in vitro, laboratory ani-
mal, ecotoxicology, epidemiology) is evaluated first indi-
vidually and then collectively, using the principles of
toxicology, epidemiology and endocrinology [41]. EDC
data are often derived from multiple lines of evidence,
and these different types of data need to be evaluated
and integrated carefully. Thus, this process is an expan-
sion of methods used in clinical sciences, which typically
focus on evidence from human studies, as it incorpo-
rates both systematic review and integrated assessment
(SYRINA) of different lines of evidence. With regard to
EDCs, the overall objective of using the SYRINA frame-
work is to provide a sufficient evidence base needed to
support decision making, including any action to avoid/
minimise potential adverse effects of exposures.
Importantly, the use of the proposed framework allows
scientists, clinicians and risk assessors to consider all
evidence and knowledge when drawing conclusions ra-
ther than identifying so-called ‘key studies’ which is the
current principle [42–45]. Further, this framework will
allow for transparent application of expert judgement,
which has been identified and debated as a critical issue
in chemical risk assessments [5, 44, 46]. In systematic re-
view, topic specific expertise is required to develop and
implement a high quality protocol. Although expert
judgement is unavoidable and plays a critical role in haz-
ard and risk assessment, it inevitably introduces value-
based assumptions to the assessment that may influence
the conclusions. The use of expert judgement in ways
that are not transparent nor consistently applied may in-
crease discrepancies in hazard and risk assessment con-
clusions, often rendering them irreproducible between
Table 1 Key elements of a systematic review protocol
A well-defined study question
A reproducible, transparent literature-search strategy
Pre-determined method(s) used to screen studies based on inclusion/
exclusion criteria
A method for evaluation of internal validity of included studies
A summarization of findings from included studies
A method for rating the quality of the evidence across studies
Procedures to synthesize data within individual evidence streams,
including decision criteria, using standard terms
Methods to integrate multiple streams of evidence and reach uniform
classifications based on objective criteria
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experts [47–49]. It is therefore of key importance that
any assumptions are transparently described prior to ini-
tiating the review to the extent possible. For example, a
scientist examining rates of thyroid cancer might focus
on the role of thyroid hormone receptor agonists and
antagonists while ignoring compounds known to act as
anti-androgens, which have no known role in the eti-
ology of this disease; thus, a systematic review might opt
to focus only on thyroid disrupting compounds, based
on an assumption that compounds with a mechanism of
action relevant to androgen signaling do not have rele-
vance to thyroid cancer. This type of a priori assumption
should be described transparently so that new informa-
tion identified in the future that might challenge this as-
sumption can be appropriately considered.
Importantly, our proposed framework is focused on
the defintion for EDCs proposed by the IPCS/WHO in
that it evaluates both endocrine disrupting actvity and
(adverse) effects. Because different definitions and cri-
teria for EDCs are used by authorities in different na-
tions [50], policy and regulatory decisions may only
require evidence of endocrine activity or (adverse) ef-
fects. If other definitions of an EDC are used in
decision-making, a revised format of the SYRINA frame-
work proposed here can be used. This is discussed in
greater detail later in this manuscript.
Throughout the process, we recommend that re-
viewers keep in mind and identify the key knowledge
and data gaps, uncertainties, and variabilities to establish
confidence in the evaluation and to help users of the
SYRINA review distinguish between what is known and
what is not known. These issues are also discussed in
more depth later in the manuscript, but require consid-
eration throughout each step of a systematic review.
The proposed framework
We have developed a framework for the SYRINA of en-
vironmental chemicals to determine whether they are
EDCs and to assess the strength of association between
exposure and adverse outcome. This framework, sepa-
rated into seven steps, is described in detail below and
shown in Fig. 1.
Step 1: Formulate the problem
The first step in the process is to define the overall
objective/problem and formulate (an) answerable re-
view question(s). Defining the review question(s) will
guide the review process and give the scope of the
evaluation. It is important to engage topic-specific ex-
perts, with fully disclosed information about potential
conflicts of interest, early in this process to provide
context and ensure its accuracy, relevance and trans-
parency [44]. Review question(s) should be selected
that are feasible, tractable, of high priority, not
duplicative, and have a high potential to impact
decision-making (considering the time and effort re-
quired to conduct a systematic review). Key questions
and objectives should also reflect areas of uncertainty.
Finally, the objective/problem and review question(s)
are formulated as a statement describing Populations
of interest, Exposures, Comparators, and Outcomes
(PECO) based on the Cochrane PICO statement [27],
where the “I” for Intervention is replaced with an “E”
for Exposure (Table 2). The quality of exposure as-
sessments is often critical for observational studies.
The PECO statement serves as a guide for the entire
review process including the literature search strategy,
criteria for the inclusion/exclusion of studies, type of
data extracted from studies, and strategy for synthesis
and reporting of results [38, 51–55].
Each evidence stream – mechanistic (non-animal, animal
or human), laboratory animal, wildlife (epidemiology), and
Fig. 1 Structure of the proposed framework for the systematic
review and integrated assessment of endocrine disruption
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human (epidemiology) – may have its own PECO state-
ment. For example, relevant ages of participants in a hu-
man study can be specified under “Population”; specific
windows of exposure can be specified under “Exposure”.
The important aspect of the PECO statement is that the
types of studies to include in the review are made prior to
literature identification. These decisions are therefore not
determined by the results of the studies, but rather based
on what aspects of the study are relevant to answer the
overarching question.
The PECO statement will differ depending on the type
of review question to be answered as well as the frame-
work being used to assess the compound of interest. For
example, a PECO statement might simply ask whether a
compound is associated with a specific disease outcome,
in which case the mechanism by which the chemical acts
need not be evaluated. Alternatively, when the IPCS/
WHO definition of an EDC is used as the basis of the
PECO statement, separate questions related to the asso-
ciation between the chemical and an (adverse) effect, the
association between the chemical and an endocrine
mechanism as well as the plausibility of the link between
the effect and the endocrine disrupting activity must be
addressed [14].
The PECO statement will also be influenced by
whether exposures in populations (human, wildlife) are
defined and ongoing. For example, when a new com-
pound is produced, it may be possible to evaluate
whether some endocrine disrupting properties are iden-
tified (and also whether health effects are likely in a
population of interest) prior to an actual exposure of
that population. In this case, the PECO statement should
carefully consider anticipated uses of the chemical, and
transparently document the assumptions that were made
about potential exposures (routes of exposure, doses, life
stages, etc.).
The writing of the PECO statement is perhaps the
most important step in the SYRINA framework. How
the PECO statement is constructed will influence the
depth of the questions that can be answered, and which
conclusions will be reached. For example, a PECO state-
ment that focuses on the anti-androgenic actions of a
chemical may prevent the assessment of evidence indi-
cating that the chemical interferes with thyroid hormone
signalling. For this reason, multiple PECO statements
are likely to be needed to fully evaluate the available lit-
erature on any select compound.
Step 2: Develop the protocol
A protocol is a document that lays out the steps of the re-
view in sufficient detail to allow other investigators to re-
peat the processes described; key elements of the protocol
are described in Table 1. Development of a protocol is
standard for systematic reviews in clinical medicine [25,
27, 56] and the practice is becoming standard in reviews of
preclinical animal data [57–59]. Methods for conducting
systematic reviews in environmental health similarly de-
scribe the importance of developing a protocol [28, 29, 35,
38]. The protocol serves as the blueprint for the methods
that will be used to identify and evaluate the evidence; it
provides transparent documentation of the methods to be
used, serves as a basis for training reviewers, and reduces
bias and errors in the assessment of the literature (since
methods are clearly defined, in writing, and developed
prior to the start of this assessment rather than basing the
review on the findings during the assessment) [27, 38].
The protocol can change during the review process in
light of unanticipated issues which only become appar-
ent during data evaluation. Changes to the protocol
should be documented at the time that they are made so
that they can be disclosed in a transparent manner when
the final evaluation is completed. Protocols should also
Table 2 Elements of a PECO statement using PFOA and birth weight as an illustrative example
Element Explanation Example for perfluorooctanoic acid
(PFOA) and birth weight in animals
(adapted from [54])
Example for perfluorooctanoic acid
(PFOA) and birth weight in humans
(adapted from [53])
(P) Population Condition or disease, characteristics/
demographics of the participants.
Which setting?, e.g., general population,
occupational setting
Laboratory rodents exposed to
PFOA in utero, assessed in early
postnatal life
Humans that are studied during
reproductive/developmental time
period (before and/or during
pregnancy or development).
(E) Exposures What are the exposures of interest? What
types of chemical(s), what is the timing of
exposure that will be considered? Which
duration/frequency of exposure or timing
of follow-up in relation to exposure?
Exposure to perfluorooctanoic acid
(PFOA), CAS# 335-67-1, or its salts
prior to mating, or during pregnancy
Exposure to perfluorooctanoic acid
(PFOA), CAS# 335-67-1, or its salts
during the time before pregnancy
and/or during pregnancy for females
or directly to foetuses
(C) Comparator Which exposure groups will be compared
to each other (high versus low exposure)
(exposure versus control)?
Exposed groups versus vehicle-treated
or naïve controls
Humans exposed to lower levels of
PFOA than the more highly exposed
humans.
(O) Outcome Which outcomes will be included or
covered? Consider adverse effects as
well as potential adverse effects.
Body weight during first five days of
postnatal development, total litter weight,
measures of size such as body length
Effects on fetal growth, birth weight,
and/or other measures of size such as
length.
Vandenberg et al. Environmental Health  (2016) 15:74 Page 5 of 19
be registered with protocol repositories such as PROS-
PERO (http://www.crd.york.ac.uk/PROSPERO/) which
includes systematic reviews related to environmental
health as a demonstration of transparency and open dis-
closure of the review methods prior to its undertaking
[60]. A suggested format for a protocol is given in de
Vries et al. [59]. The peer-reviewed open-access journals
Environmental Evidence (http://environmentalevidence-
journal.biomedcentral.com/) and Evidence Based Preclin-
ical Medicine (http://onlinelibrary.wiley.com/journal/
10.1002/(ISSN)2054-703X) publish systematic review
protocols and methodological papers related to the con-
duct of systematic reviews.
Step 3: Identify relevant evidence
Within the protocol, a structured framework should
provide details for each aspect of the studies to be evalu-
ated; these evaluation criteria provide a basis for decid-
ing which studies are included or excluded.
Exclusion and inclusion criteria are derived from the
PECO statement. Results of studies (e.g. whether find-
ings are statistically significant, or “positive” or “nega-
tive”) are not appropriate criteria for exclusion or
inclusion. Similarly, compliance with standardized test
guidelines such as OECD test guidelines, or Good La-
boratory Practices (GLP), is not an appropriate criterion
for exclusion or inclusion.
The study flow diagram is a required element of a sys-
tematic review that is used to depict the flow of informa-
tion through the different phases of the evaluation
(Fig. 2). It maps out the number of included and
excluded records identified, and the primary reasons for
exclusions at the full text level [61].
Step 3A: Performing searches
The goal of the search strategy is to provide a system-
atic, objective, reproducible and comprehensive search
of the literature relevant to the objective of the review.
This is a key feature in clinical systematic reviews and a
key step in reducing bias in the overall evaluation [27].
The goal and steps of the search strategy are defined in
the protocol. Decisions about the scope of the search are
also made, including the databases to be searched and
the types of data that will be considered. For example,
during the database search stage, decisions should be
made about what type of literature should be considered,
e.g. peer-reviewed articles, agency reports, consultancy
and industry studies, and other proprietary data.
Additional file 1: Table S1 outlines data sources that
may be relevant when searching for studies related to
environmental chemicals. Some have limitations in their
search approaches such as character limits and inabilities
to support Boolean logic and to export results. Depend-
ing on the affiliation of the reviewer, access to these dif-
ferent types of literature may vary. Decisions also have
to be made regarding how to address studies written in
different languages, studies published only in abstract
form, and unpublished results. In general, use of non-
English literature is encouraged and has recently become
more achievable with online translation tools. Confer-
ence abstracts, theses and dissertations may contain rele-
vant data and decisions should be made before starting
Fig. 2 Example study flow diagram
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the review as to whether they will be included. Other
sources of information may come from publicly available
databases, such as the US National Toxicology Program
(NTP)’s Tox21 and US EPA’s ToxCast high-throughput
screening platforms. These results may be very relevant
to EDCs so they should be considered for inclusion in
the protocol.
The literature search should be developed and per-
formed in consultation with a specialist, in particular
a trained librarian or a person experienced in system-
atic review. Others involved in this process include
the evaluation team and, as needed, subject matter
experts. Typically, the search strategy is developed by:
(1) identifying PubMed’s Medical Subject Headings
(MeSH) for relevant and appropriate terms, (2)
extracting key terminology from relevant reviews and
a set of previously identified primary data studies that
are known to be relevant to the topic, identified in
consultation with the expert team, and (3) reviewing
search strategies presented in other reviews. The
search strategy may be tailored to make it suitable to
other non-PubMed databases such as Web of Science,
Scopus, etc. In these circumstances a number of re-
lated search strategies might exist, each designed for
a specific database.
The search strategy, date of search, and publication
dates included in the search should be documented with
sufficient detail so that the search can be reproduced, al-
though replication of the exact search results may not be
possible as databases change over time. It may be useful
to update the literature search at a specified time inter-
val during the evaluation, to capture literature published
during the course of the evaluation. This should be de-
fined in the study protocol, perhaps conditionally (e.g. if
the review is not completed within 12 months of the
search, a further search will be performed). The investi-
gators’ awareness of new research published after the
cut-off date for inclusion is not a valid reason for con-
ducting a new search.
Finally, after identifying the studies to be included, the
studies’ citations should be evaluated to ascertain if there
are any additional relevant records or sources of data
that should be included as evidence. Any additional
identified studies are then evaluated as below using the
same inclusion and exclusion criteria.
Step 3B: The screening process
To determine their relevance and eligibility for inclu-
sion or exclusion, articles are independently screened,
typically by at least two investigators. There are mul-
tiple software platforms that facilitate a more uni-
form approach to the screening process including
DistillerSR®, Rayyan, or Health Assessment Work-
space Collaborative (HAWC).1 Results from the
search are first sorted and any duplicates are re-
moved (e.g. using validated tools for duplicate re-
moval [62]). Next they are reviewed by title and
abstract using the developed screening instructions.
The goal here is first to screen out any articles that
are obviously not relevant to the PECO statement.
Next, remaining articles undergo a full-text review
using the same screening instructions as for the ab-
stracts. After each step in the process, differences in
evaluation between reviewers are identified and re-
solved via discussion. Machine-learning approaches
to prioritizing articles for relevance during screening
are also becoming more acceptable for use [63].
At the conclusion of Step 3, the final product is a
group of studies that have been deemed applicable to
the PECO statement written in Step 1. These studies, se-
lected using transparent and reproducible methods, are
then used as the basis for the remainder of the evalu-
ation (Steps 4–7).
Step 4: Evaluation of individual studies
The purpose of Step 4 is to evaluate the quality of indi-
vidual studies identified in Step 3. Study quality is a gen-
eral concept; in the context of evaluating studies for
hazard assessment, different definitions of ‘study quality’
have been used across scientific disciplines. Nevertheless,
in the context of all disciplines, the purpose of study
quality assessment is to evaluate aspects of the study
that might influence the interpretation of the results
such as the selection, validity, reliability, and/or sensitiv-
ity of the methods used.
In systematic review methods developed in the fields
of medicine and health care, focus is placed on evalu-
ating a study’s internal validity. Risk of bias is one
term that has been used for this concept, and is de-
fined as “the extent to which flaws in the design and
execution of a collection of studies could bias the esti-
mate of effect for each outcome under study” [64].
Where bias refers to systematic error that reduces val-
idity, risk of bias is the “potential that bias has oc-
curred” [65]. In a recent and comprehensive report,
the National Academy of Sciences identified sources
of bias in experimental studies (i.e. laboratory animal,
in vitro mechanistic) including [65]:
 selection (differences between controls and treated
groups at baseline),
 performance (differences in how controls and
treated groups are handled throughout the
experiment),
 detection (differences in how outcomes in controls
and treated groups are assessed), and
 exclusion (differences in how controls and treated
groups are removed from the study).
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The National Academy of Sciences also identifies
sources of bias in observational studies (human epidemi-
ology and wildlife studies) including [65]:
 confounding (differences between the distribution of
risk factors between exposure groups, which could
occur at baseline or at other points during follow-
up),
 measurement (mismeasurement of exposures,
outcomes or confounders at any point during the
study), and
 reporting (selective reporting of outcomes, analyses,
or whole studies)
Studies that have inadequate randomization of subjects
or fail to use blinding for participants or evaluators are
typically considered to have a high risk of bias.
While the concept “risk of bias” is well known in the
fields of medicine and health care, its use is still being
introduced into the field of environmental health sci-
ences and chemical risk assessments. In some areas,
especially when evaluating experimental data for regula-
tory risk assessment within the EU, the term reliability
is commonly used as a descriptor of study quality [66].
In this context, reliability is defined as the inherent qual-
ity of the study and is tightly linked to the reliability of
the methods used and how the results have been inter-
preted, as well as to how both methods and results have
been reported [66]. It is thus similar to but not as spe-
cific as risk of bias.
Evaluation of individual studies in each data stream
Numerous tools exist to capture judgements about study
quality; these tools were typically designed for the evalu-
ation of either observational studies (human epidemi-
ology and wildlife) or experimental studies (in vivo or in
vitro studies). Examples of tools that are applicable for
incorporation into the SYRINA are summarized in Add-
itional file 1: Table S2-S5. When selecting one of these
tools, it should be applied to the assessment of all
studies in each data stream. These tools typically pro-
vide tables that can be filled in by evaluators that will
summarize each study individually. Below, we
summarize approaches for the different types of data
streams. We recommend against the use of tools that
assign a numerical score for study quality as these can
imply a quantitative measure of scientific uncertainty
that is misrepresentative.
Human epidemiology
Work in evaluating the internal validity of human epi-
demiology studies in the field of clinical medicine fo-
cused on risk of bias in randomized clinical trials [27,
29, 32]. A number of more recent approaches for
evaluation of nonrandomized studies of clinical interven-
tions and environmental health studies have also been
developed and applied (see Additional file 1: Table S2).
One such approach, the “Risk of Bias In Nonrandomized
Studies - of Interventions” (ROBINS-I) method, has re-
cently been released [67]; other approaches have been
developed by academic groups (i.e., the Navigation
Guide) or national or international agencies. Consider-
ation of the predicted direction and magnitude of bias
(if possible) is explicitly included in these methods,
allowing the appraiser to note whether an observed ef-
fect estimate is likely to be an over- or under-estimate of
the true effect estimate.
Consideration of the possible roles of bias, confound-
ing and chance in the interpretation of epidemiological
studies is an essential component of cancer hazard iden-
tification by the IARC and by the US NTP ORoC [31,
37]. These evaluation methods systematically consider a
number of aspects of design and analysis to inform the
extent to which these factors have been minimized in an
individual study. Specific aspects concern the study
population, methods used to ascertain disease(s), and to
measure exposure; consideration, in design and analysis,
of potential confounding variables; other attributes of
the analysis that can influence the robustness and inter-
pretation of the results, reporting considerations; and
statistical analyses. Emphasis is given to the appropriate
use of meta-analyses and pooled analyses to increase
precision and to explore potential heterogeneity.
When considering the use of any tool or method for
the assessment of EDC epidemiology studies, several im-
portant aspects of these methods should be highlighted.
First, evaluation of exposure measures is often limited
and exposure misclassification is one of the most im-
portant issues in epidemiology studies [68]. In addition,
a crucial issue with respect to EDC exposures is how
well the measure reflects exposure in the etiologically
relevant time window for the specific outcome under
study. Other aspects of the “sensitivity” component of
quality of epidemiological studies (i.e., the ability of the
study to detect a true effect of exposure when one exists,
similar to the concept of the sensitivity of an assay) may
need to be explicitly considered with additional ques-
tions and criteria [69]. Potential modification of the bias
domains for application to human epidemiology studies
are shown in Additional file 1: Table S3.
Wildlife studies
Wildlife studies are typically observational in nature,
identifying and investigating a disease or disorder and
the underlying factors that lead to these conditions.
Using study designs similar to those used in human
epidemiology, they investigate the presence or ab-
sence of associations between exposures and health
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outcomes on individual wildlife species, and the likely
or measured impacts at the population and ecosystem
levels. In ecological risk assessments, population-level
impacts take precedence over effects observed in individ-
uals. In the current SYRINA framework, observational
wildlife studies can be evaluated using the human frame-
work, as the same evaluation of the methods applies. We
therefore recommend using the same approach as de-
scribed above for human epidemiology studies (Additional
file 1: Table S3).
Observational wildlife studies may be complemented
by experimental studies (e.g. caging, mesocosms, whole
ecosystem studies) in which wildlife populations or indi-
viduals are intentionally exposed to an EDC or chemical
mixture. For these experimental studies, risk of bias and
study quality should be assessed using the tools devel-
oped for in vivo toxicity studies (see below).
In vivo (Mammalian and Non-mammalian) and in vitro
toxicity studies
Regulatory agencies and organizations such as the Euro-
pean Chemicals Agency, the US Food and Drug Admin-
istration (FDA), and the OECD have promoted the use
of the Klimisch method [70] for the evaluation of study
quality in toxicity studies. However, there are several
challenges with using the Klimisch method, including
that 1) no detailed criteria and very little guidance for
study evaluation is provided, 2), Klimisch focuses solely
on quality of reporting, so that studies conducted ac-
cording to standardized test guidelines and GLP are by
default attributed higher reliability than other research
studies and 3) there is no evidence that GLP studies
have a lower risk of bias. Reliance on standardized test
guidelines is especially problematic in the context of
identifying and assessing EDCs since research using
novel methods may be more sensitive and relevant for
assessing endocrine-related outcomes [12, 42, 45, 71–
74]. Comparisons and testing of different evaluation
methods, including the Klimisch method, show that
there is variability in their development and content,
and this affects the outcome of evaluations [45, 74].
The National Academy of Sciences states that “con-
ducting an animal study according to [GLP], or by com-
plying with human-subjects guidelines for a clinical
study” ensures that the research was conducted using
high standards [65]. However, the National Academy of
Sciences also notes that this consideration does not rep-
resent the totality of what should be included in the
evaluation of individual studies. We note that GLP is a
method for ensuring adherence to protocols and study
reporting, and does not ensure that a study had a high-
quality design. There are clear examples of how a study
could follow GLP but fail to consider these other im-
portant aspects of study design (e.g. contamination of a
negative control group, inappropriate laboratory tech-
nique, improper reporting of animal ages, failure of a re-
sponse in a positive control group, etc. [43, 75–77]); in
these types of circumstances, these studies should not be
deemed high quality.
Several new evaluation methods have been devel-
oped that better target internal validity of in vivo or
in vitro toxicity studies, and provide more structured
support for determining a study’s adequacy for hazard
and risk assessments. Additional file 1: Table S4 pre-
sents an overview of recently developed evaluation
methods for in vivo toxicity studies (including non-
mammalian aquatic species) that could be used for
EDCs. These methods offer detailed criteria and guid-
ance to help risk assessors and others conducting
SYRINAs to make use of all available studies. In
addition, the methods promote increased transparency
and structure of the evaluation process. Relatively few
methods have been developed for the evaluation of in
vitro toxicity studies (Additional file 1: Table S5), and
only one tool has undergone pilot testing.
In silico data
For the purpose of this review, in silico methods are
limited to those that predict the potential for a par-
ticular chemical structure to cause “endocrine disrup-
tion”. These often include computational methods
that derive structure-activity relationships (SAR) and
thus predict potential EDC activity for a given chem-
ical structure. SAR methods can also provide an un-
derstanding of the variations in chemical structures
that contribute to variations in EDC activity. Table 3
summarizes our recommendations regarding require-
ments to evaluate in silico data. The REACH legisla-
tion provides guidance for use of quantitative SAR
(QSAR) models [78], dictating conditions for the
underlying mechanism, the modelling method and the
assessment of reliability. The OECD also provides
guidance on how to evaluate in silico data [79].
Step 5: Summarize and evaluate strength of each stream
of evidence
The development of the SYRINA framework considered
the viewpoints proposed by Austin Bradford Hill [80],
which were proposed within the context of evaluation of
epidemiology studies. Importantly, many systematic re-
view methods have adopted the approach of GRADE,
which provides guidance on how to utilize a structured
framework for assessing overall quality of the evidence.
As discussed below, the factors considered by GRADE
overlap with many of the Bradford Hill considerations
but provide guidance on how to operationalize and are
expanded to include publication bias [81]. The Cochrane
Collaboration has adopted the principles of the GRADE
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system for evaluating the quality of evidence for out-
comes reported in systematic reviews.
The purpose of this step is to summarize relevant data
from the individual studies evaluated in Step 4, and to
synthesize the evidence within each stream (e.g., human
epidemiology, wildlife, laboratory animal, in vitro, in
silico). If using the IPCS/WHO definition of an EDC
[14], two types of evaluations should occur during this
step: each stream of evidence is evaluated for the ques-
tion of “strength of evidence for [pre-determined] effect”
and then again for “strength of evidence for endocrine
disrupting activity”. In this case, at the end of this step,
the evidence within each stream will be characterized by
a pre-defined descriptor (see Table 4 for examples) de-
scribing the confidence in the association or strength of
evidence pertaining to each of two relationships:
 Association between chemical exposure and
(adverse) effect (Step 5a)
 Association between the chemical and endocrine
disrupting activity (Step 5b)
The plausibility of the link between these two factors,
as required by the IPCS/WHO definition of an EDC, is
assessed in Step 7.
Step 5A: Analysis of the strength of association between
exposure and (adverse) effect within evidence streams
In this step, the evaluation of studies from Step 4 is
combined with additional considerations to draw
conclusions about the strength of evidence within
each stream. Approaches have been developed and
applied by the OHAT/NTP and the Navigation Guide
and integrate best practices used in evaluating overall
evidence from IARC and US EPA [82]. These have
been recently reviewed by the National Academy of
Sciences [65].
In methods based on GRADE (e.g. the Navigation
Guide and OHAT approaches [25, 83]) the strength of
evidence from each stream is assessed in two stages. An
initial confidence rating is modified by aspects of qual-
ity (e.g., risk of bias considerations) and other factors
that can lower confidence (inconsistency, indirectness,
Table 3 Evaluation methods for in silico models
Modeling type Description of the method
For all modeling work: ▪ Standardization and curation of the investigated dataset to ensure consistency. This should include a clearly-stated
method (including inclusion and exclusion criteria) for curation of the data and a review of the rules applied to
chemical structures in order to ensure standardization
QSAR models: ▪ Use of sufficiently diverse training set covering the EDC compound domain of interest
▪ Use of sufficiently diverse external test set covering the EDC compound domain of interest should be used
▪ Assembly of internal and external validation, i.e. several internal and external validation sets, and models created
in a double loop fashion, followed by consensus predictions
▪ Sufficient statistical quality achieved
▪ Consistent applicability domain established, e.g. using a conformal prediction framework
For ligand based
pharmacophore models:
▪ Use of sufficiently diverse training set covering the EDC compound mechanism/domain of interest
▪ All training set compounds should, approximately, fit the derived model equally well unless there are demonstrable
differences in the binding affinity
▪ Use of sufficiently diverse external test set that covers the EDC compound domain of interest to demonstrate
generalizability
Protein structure based models: ▪ Several protein structures should be used to account for flexibility of the protein covering relevant conformations
▪ Use of sufficiently diverse training set covering the EDC compound domain of interest
▪ Consensus docking and scoring to ensure robustness and stability of results
▪ Use of sufficiently diverse external test set covering the EDC compound domain of interest
Table 4 Example descriptors that can be used to characterize confidence in the strength of the evidence between two factors (like
exposure and adverse outcomes) within a data stream
Descriptor Explanation
High New research is unlikely to change the conclusions drawn from the currently available studies; conclusions are based on a set of studies
in which chance, bias, confounding and other alternative explanations can reasonably be ruled out.
Medium New research could affect the interpretation of the findings. Conclusions are based on a set of studies in which chance, bias,
confounding or other alternative explanations cannot reasonably be ruled out as explanations.
Low The available studies do not allow an inference regarding toxicity because of limitations such as inadequate sensitivity or relevance of
the study designs.
Absent No studies available.
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imprecision, or publication bias) or raise confidence
(magnitude of the effect, dose–response gradient, direc-
tion and impact of residual plausible confounding, and
consistency across evidence streams). One way to assess
consistency is to generate visual displays of the results
across studies. Several types of displays can be useful,
including exposure- (or dose-) response graphs depict-
ing effect size in relation to exposure level in one or
more studies, and forest plots that typically depict ef-
fect size for each study in a set of studies [84]. Al-
though forest plots do not depict exposure level along
an “x axis”, studies can be grouped by various factors,
such as exposure level, to examine patterns. The
process of sorting and grouping, in particular, stratifica-
tion by quality assessment (overall, and for specific risk
of bias domains) or by exposure level, is the foundation
for examining the question of whether reasonable ex-
planations can be made for the patterns seen across
studies. Analysis of these factors results in confidence
or strength of evidence rating categories for each
stream: “high”, “medium”, “low” and “absent” (i.e. no
studies available) (Table 4).
We recommend that the initial rating for experimental
laboratory animal studies should be set as “high” based
on the approach in clinical medicine, where randomized
clinical trials (i.e. controlled and randomized exposure
studies with the inclusion of a relevant control group)
are rated “high”. For epidemiology studies, the choice of
the initial confidence rating for the GRADE-based
methods is an issue that is undergoing research and re-
view. “Medium”, has been recommended for an initial
rating of observational (epidemiology) studies [30, 85];
another option is to start all studies as high (i.e., the top
rating level); this rating could subsequently be modified
by the risk of bias evaluation. The National Toxicology
Program ORoC bases the initial confidence rating on the
evaluation of the studies (Step 4) rather than on an a
priori designation for all studies of a given design. The
evaluation process results in an overall rating for the
confidence (or risk of bias) for each study. Thus, for ex-
ample, results from a set of high confidence would be
given an initial confidence rating of high. The confi-
dence level is then modified based on considerations
that overlap with those used by the National Toxicology
Program OHAT and Navigation Guide (Additional file 1:
Figure S1). Results from low confidence (high risk of
bias) studies can supplement, but would not negate or
override the conclusions drawn from higher confidence
studies.
Following this initial rating, evidence streams are
up- or down-graded according to specified features of
the body of evidence. The following factors should be
considered to downgrade confidence in a stream of
evidence:
 limitations in methodological quality of the research
in the stream (including risk of bias across studies)
 important and unexplained inconsistency in study
results within the stream
 imprecise or sparse data
The following factors can be considered to upgrade
confidence in a stream of evidence:
 large magnitude of effect
 consistency across different study designs or species
 dose response gradients observed in similar studies
 confounding is minimized
These adjustment factors are not scored numerically
[27] but should be considered transparently as part of
the process and are evaluated as to whether overall rat-
ing should be upgraded or downgraded.
As part of the analysis of consistency and to aid in
the interpretation of the quality of the evidence, if
possible, a meta-analysis of some or all of the studies
within a stream of evidence should be conducted to
calculate a summary effect estimate. This summary es-
timate can provide a more precise estimate of the
magnitude of effect than an estimate from an individ-
ual study. For the purpose of hazard identification,
however, a single effect estimate may not be needed,
as the focus is on examining patterns and variability
(consistency) across studies. If a meta-analysis is con-
ducted, the validity of the assumption that the studies
are examining a common effect estimate must be care-
fully considered; this consideration requires more than
a statistical test of heterogeneity [85, 86]. Study qual-
ity, exposure level, exposure route, species, and nu-
merous other considerations may contribute to the
observed results and to heterogeneity among studies.
If a meta-analysis is conducted, the synthesis must
also include a discussion of the results from studies
that did not contribute to the combined analysis, for
example because their results could not be converted
into the form used in the meta-analysis.
After conducting this process, a confidence descriptor
(e.g., strong, moderate, weak, absent) is generated for
the strength of evidence for each evidence stream. Confi-
dence descriptors can also be used to summarize studies
that conclude that no effect was observed. The confi-
dence descriptor produced in this step designates con-
clusions related to the association between exposure and
adverse effects: e.g. “We have high/medium/low confi-
dence that exposure to compound X is associated with
adverse outcome Y in humans (or causes outcome Y in
animals).” Confidence descriptors can also be used to
summarize studies that indicate that no effect was ob-
served. Confidence descriptors should not be used to
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characterize the strength of the effect associated with ex-
posure to the compound (e.g. it is not appropriate to use
this evaluative tool to say, Chemical X has a strong/mod-
erate/weak ability to produce adverse outcome Y.).
Step 5B: Analysis of the strength of association between the
chemical and endocrine disrupting activity within streams
A similar process to that described in Step 5A can be
used for the synthesis of studies aimed at addressing
endocrine mechanisms; a set of considerations are ap-
plied to conclusions drawn from a group of studies.
Again, we propose the same four-level rating system to
summarize the strength of evidence in each stream:
“high”, “medium”, “low” and “absent” (no studies avail-
able) (Table 4).
After conducting this process, a confidence descriptor
(e.g., high, medium, low, absent) is again generated for
the strength of evidence for each evidence stream, but
this descriptor is related to the association between the
chemical and endocrine disrupting activity: e.g. “We have
low/medium/high confidence that compound X is associ-
ated with Y endocrine disrupting activity in experimental
animal studies.”
Step 6: Integrate evidence across all streams
The purpose of this step is to integrate the streams of
evidence that were assessed in Steps 5A and 5B to come
to a conclusion about the overall strength of the evi-
dence for endocrine disruption. First, the individual
streams of evidence need to be integrated to assess the
strength of the evidence relating to the association be-
tween exposure and an adverse effect (Step 6A). Second,
the strength of the evidence for each of the conclusions
from Steps 5A and 5B are integrated to reach a conclu-
sion about endocrine disrupting activity (Step 6B).
Step 6A: Integration of evidence: outcome/adverse effect
The aim of this step is to assess the overall strength of
evidence that exposure to a potential endocrine dis-
ruptor is associated with a health outcome. This is a
function of the combined certainty of each stream of
evidence. The first step in the process is to use a matrix
(Fig. 3) to assign an initial value to the strength of the
evidence acquired from observational evidence streams
(i.e. human or wildlife studies) and experimental in vivo
evidence streams. Based on the combined strength of
the observational and experimental streams, the strength
of the evidence for the association between exposure to
the substance and a health outcome is characterized as
“strong”, “moderate”, “weak,” or “no data”. Here, the
overall strength of the evidence achieved from integrat-
ing multiple streams of evidence will be at least as high
as the highest strength of evidence obtained for any sin-
gle stream. This value can be adjusted up one step, i.e.
from “weak” to “moderate” or from “moderate” to
“strong”, if there is high confidence in the evidence from
in silico and in vitro studies. Explanations of the terms
“strong”, “moderate” and “weak” should be developed as
part of the systematic review framework.
Most importantly, the result of this assessment can po-
tentially yield a health hazard classification independent
of any endocrine disrupting effects of the compound
under review, i.e. this step can allow for a conclusion
that “We have strong evidence that exposure to com-
pound X causes adverse outcome Y” even if no informa-
tion about endocrine disrupting properties of compound
X is available. Outside of the framework of the IPCS def-
inition of an EDC, it may not be necessary to identify
the mechanism by which a chemical acts prior to regu-
lating its use. Thus, a systematic review that solely iden-
tifies the strength of evidence linking a compound to a
health outcome may be sufficient to implement a public
health response.
Step 6B: Integration of evidence: endocrine disrupting
activity
The main aim of integration at this stage is to qualita-
tively assess evidence of endocrine disrupting activity. In
Step 5, individual streams of evidence were evaluated
and assessed with respect to this feature. Again, the
overall strength of the evidence achieved from integrat-
ing multiple streams of evidence will be at least as high
as the highest strength of evidence obtained for any sin-
gle stream (Fig. 4). The same classifiers are used to de-
scribe the strength of data in this step as in Step 6A
(Table 5).
Step 7: Conclusions, recommendations, uncertainties and
consequences
Drawing conclusions: the IPCS/WHO definition of an EDC
The IPCS/WHO definition of an EDC requires an inte-
gration of: 1) the health outcome; 2) the endocrine activ-
ity; and 3) the plausibility of the link between the
outcome and endocrine activity. To complete the SYR-
INA process, a final integration step can be accom-
plished using a matrix (Fig. 5). Confidence levels
generated in Steps 6A and 6B for evidence of the out-
come and evidence of the endocrine disrupting activity
are combined to reach preliminary conclusions for the
strength of the evidence that a compound is an EDC.
In this final step, consideration is given to the plausi-
bility of the link between endocrine disrupting activity
and outcome. The strength of the link can be used in
relatively unusual cases to up- or down-grade the pre-
liminary conclusions. Situations where the preliminary
conclusions can be downgraded include those where the
outcome is multifactorial (e.g., breast cancer) and the
evidence for the endocrine disrupting activity (e.g.,
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estrogenicity) is only ‘probable’ or ‘possible’. Similarly, it
may be appropriate to upgrade the preliminary conclu-
sion when the evidence of an outcome (e.g., decreased
male anogenital distance) has an acknowledged strong
link to endocrine activity, but data are limited to support
conclusions on endocrine activity for that particular
chemical.
The objective of a SYRINA is to provide a scientifically
supported evidence base for others to act in order to
avoid or minimise potential adverse effects, rather than
waiting to observe adverse effects in humans or the en-
vironment before any actions are taken. The conclusions
of a SYRINA will therefore include statements about po-
tential hazards. Based on the results obtained during
Step 6, these conclusions will usually take the form of
statements such as “Chemical A is a known/probable/
possible endocrine disrupting chemical based on strong/
moderate/weak evidence from human and non-human
studies.”
As noted in Step 1, the conclusions that will be
reached about the likelihood that a chemical is an EDC
will depend on how the PECO statement is framed. For
this reason, we caution against drawing overly broad
conclusions about the lack of endocrine disrupting prop-
erties of a chemical based on the results of a narrow
analysis; using the SYRINA framework, one could con-
clude that a chemical is not classifiable as an EDC based
on one PECO statement but could conclude that the
Fig. 4 Determining the strength of the evidence for the endocrine disrupting activity of a chemical. Evidence is characterized as “strong”,
“moderate”, “weak,” or “no data”. If observational or in silico data is considered strong, upgrade “weak” to “moderate”, or “moderate” to “strong”
Fig. 3 Determining the strength of the evidence for the association between exposures and (adverse) effect. Evidence is characterized as
“strong”, “moderate”, “weak,” or “no data”. If in vitro or in silico data is considered strong, upgrade “weak” to “moderate”, or “moderate” to “strong”
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same chemical is a known EDC based on another PECO
statement that evaluates different literature. For ex-
ample, a review that is focused on the anti-androgenic
effects of a suspected EDC would likely not assess the
same literature as a review focused on the thyroid hor-
mone disrupting properties of the same compound.
Drawing conclusions outside of the IPCS/WHO framework
The SYRINA framework described here was designed
specifically to address evidence of endocrine disruption
as it is defined by the IPCS/WHO [14]. Yet, there are
numerous other definitions of an EDC used by other de-
cision makers [50]. In contrast with our proposed frame-
work, some of these other definitions do not require
that health outcomes, endocrine disrupting activity and
the plausibility of the link between the two are all con-
sidered separately before a conclusion can be made [12,
16, 50]. Thus, if using these alternative definitions, a
modified version of our SYRINA could be successfully
employed. For example, evaluating exposures and health
outcomes would be consistent with many regulatory and
policy needs and is consistent with other systematic re-
view approaches. The overall structure of the systematic
review would remain the same (Fig. 1), but Steps 5 and
6 would be simplified.
It is important to note that, regardless of which defin-
ition is used, the use of the SYRINA framework requires
participation from individuals with a range of expertise.
Not only are experts in aspects of study design for each
evidence stream needed, scientific experts that under-
stand the biological processes implicated in the PECO
statement are needed (e.g. PECO statements related to
the risk of breast cancer require experts in mammary
gland biology, cancer, and other scientific fields); gener-
alized toxicology or endocrinology knowledge is not
likely to be sufficient. Without such subject matter ex-
perts, the conclusions that are drawn may be incomplete
or inaccurate.
Making recommendations
The evaluation of evidence about the potentially adverse
effects of an EDC is a different activity from deciding
how to act on the basis of that evidence. Who evaluates
the evidence and who then recommends action, based
on the available evidence, depends on the issues and
practices involved in different domains of activity and
regulatory contexts. In many regulatory agencies tasked
with addressing chemical safety, the evaluation of evi-
dence is performed by “risk assessors” whereas the rec-
ommendations for action are made by “risk managers”.
Table 5 Example descriptors that can be used to characterize confidence in the strength of the evidence after integration across
data streams
Descriptor Explanation
Strong Future research might make estimates of effect size more precise but are unlikely to show these findings to be a false positive.
Moderate Although the evidence might be suggestive of an effect, overall it cannot be judged with any confidence whether this effect is real or
not; future research may show this to be a false positive.
Weak There is insufficient evidence for inferring that exposure to the compound is associated with the (adverse) effect. Importantly, we note
that this is not equivalent to inferring that the compound is not associated with the (adverse) effect.
No data No studies available.
Fig. 5 Matrix for drawing conclusions about endocrine disruption. Note: “not classifiable” does not mean that it is not an EDC, simply that not
enough data is available to draw a conclusion
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Recommendations are typically based on both the evi-
dence of risk (or hazards), and on the availability, feasi-
bility, and cost of the options for action.
As Bradford Hill and others have addressed, there is
no direct link between the strength of evidence about a
threat (e.g. a chemical’s hazard) and the strength of rec-
ommendations about how to minimise or avoid it. For
example, information may be available only from epi-
demiology studies with designs in which bias and
confounding may be impossible to resolve, yet an inter-
vention may be strongly recommended given the serious
consequences of inaction.
Some groups may prefer to use a modified version of
the SYRINA framework where direct evidence for mech-
anism of action is not required (e.g. in a modified SYR-
INA, decisions could be made based solely on the
evidence linking a chemical to a harmful outcome,
rather than a requirement that the compound be dem-
onstrated to act via and endocrine mechanism). Mech-
anistic data can take decades to collect and to be agreed
upon by experts in the field [44, 87]. Decision makers
are faced with choices as to when and where to act on
the endocrine disrupting related causal pathway from ef-
fects to adverse effects, given the need to act before
harm to human health or environments arises, especially
if it is irreversible and or trans-generational.
Handling uncertainties
In each step of the SYRINA, as in the assessment of
chemical hazards and risk in general, there are sources
of scientific uncertainties and the possibility for error
that could contribute to false-positive or false-negative
conclusions. There are, for example, uncertainties asso-
ciated with assumptions made while formulating the
problem or review question, as well as how the PECO
statement is framed. Uncertainties also arise when ex-
trapolating from data that is only indirectly relevant to
the target population, e.g. toxicity data in other species,
or exposure scenarios that differ from actual exposure.
Incomplete or lack of data also contribute to uncertain-
ties in the final conclusions.
A specific source of uncertainty is the reliance on “sta-
tistics” in individual studies to make conclusions about
the strength of evidence. “Statistical significance” is gen-
erally achieved when the probability p that the study re-
sults deviate from expectation under the null hypothesis
is less than a limit of 5 %. However, this limit may rule
out many potentially causal associations, e.g. because the
study was too small to reach statistical significance [88].
While aiming to avoid bias toward the null (e.g. false
negatives), the risk of false positives should also be con-
sidered. There is an ongoing debate over the prevalence
of false positives in some fields of biomedical research
[89, 90]. Publication bias is always a concern, but
endocrine disruption would seem less vulnerable, as the
ratio of true to no relationship among the relationships
probed in published studies is likely much higher than
in most other fields [87]. For example, only a few per-
cent of industrial chemicals in use in the late 1970s were
considered hazardous, while that was true for about
70 % of new chemicals tested [91]. The “untested chemi-
cals assumption” therefore causes a very large propor-
tion of false negative conclusions [92]. In contrast, when
scrutinising alleged false positive findings in environ-
mental health and toxicology, very few such cases have
been found [93, 94]. Thus, the impact of publication bias
would therefore be negligible in comparison with the
false negatives due to the huge number of chemicals, for
which virtually no information exists on endocrine dis-
rupting properties.
Sources of uncertainty related to any of the steps in
the systematic review should be disclosed and character-
ized as far as possible in order to inform risk managers.
Guidance for evaluating and expressing uncertainty in
hazard and risk assessment is available from the Inter-
national Programme on Chemical Safety (IPCS) [95].
Guidance for handling uncertainties in scientific assess-
ments is also under development at EFSA.
Evaluating consequences
There is often an intermediate step between evidence
evaluation/integration and taking action and this is the
evaluation of the consequences of being wrong about ei-
ther the evaluation or the threat. For example, at this
stage it is important to consider the consequences of be-
ing wrong about a chemical being hazardous, or the
consequences of a failure to act following evidence that
an EDC is hazardous. As the consequences of being
wrong in both cases can be serious, and sometimes irre-
versible, they may need to be evaluated and reported by
evidence evaluators whose expertise contributes to such
consequence analyses.
The plausibility and likelihood of being wrong with an
evaluation of evidence is related to the confidence that
evaluators have placed in their conclusions. We propose
that this confidence can be increased by using transpar-
ent and reproducible methods that acknowledge uncer-
tainties during the process of completing a SYRINA.
Future research needs
The SYRINA framework described in this manuscript
provides methods to critically evaluate scientific litera-
ture. Like the methods on which it is based (OHAT and
Navigation Guide), there is a need to explore and evalu-
ate the best use of these tools in hazard identification
and regulatory contexts and from these experiences, and
improve these methods for greater efficiency and trans-
parency. Several areas have been identified in this review
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as short-term needs including the development of
methods for evaluating in vitro and in silico data. We
note the need for a case study which would also shed
light on important procedural issues, including the num-
ber and types of experts needed to evaluate evidence
from different scientific fields. Such a case study would
also be important to identify the time required to
complete Steps 1–6 of SYRINA based on examples with
many relevant studies versus other examples with min-
imal available data. We anticipate that the completion of
Steps 1–6 could take more than a year to conduct if a
relatively large dataset is identified; importantly, this
could lead to further delays in the already lengthy pro-
cesses for regulatory decision-making and other public
health oriented actions. We also note that some risk as-
sessment groups will need to make concrete decisions
about how PECO statements are written and which risk
of bias tools are used in evaluation of studies within evi-
dence streams, as this level of consistency is needed to
produce harmonized evaluations.
In fall 2015, the US National Academy of Sciences
convened a panel specifically to evaluate the data in sup-
port of “low dose effects” for environmental chemicals
including EDCs. (For narrative reviews of the ‘low dose’
literature, see [96, 97].) The National Academy panel
specifically aims to use systematic reviews to evaluate
the published literature, and therefore might benefit
from use of the SYRINA framework. Work from this
panel will continue through 2016, and may include one
or more case studies, providing additional evidence
about the feasibility of systematic reviews with broad
goals [41].
The IPCS/WHO definition of an EDC raises another
important future research need: the delineation of effects
as adverse (or not) has been a source of significant de-
bate [16, 17]. In the absence of a definition of ‘adverse
effects’ by many risk agencies, decisions on adversity are
left to the discretion of individuals. This application of
expert judgement is rarely transparent, which is prob-
lematic in the context of a systematic review.
Conclusions
A number of recent analyses of the EDC literature
were criticized for failing to use systematic review
methods to draw their conclusions. Importantly, sys-
tematic review processes specific to EDCs were not
yet available for use in these reports. Here, we have
developed a seven-step framework for the systematic
review and integrated assessment of EDC studies; this
framework has a direct application to the IPCS/WHO
definition for EDCs. It is also amenable for use in the
context of other definitions of an EDC or, with some
minor modifications, it could be used to conduct sys-
tematic reviews of environmental chemicals that are
not EDCs. The SYRINA framework can be used in
hazard assessment, which encompasses the first step
of the risk assessment process.
The implementation of the SYRINA framework will
enhance the assessment of the EDC literature, allow-
ing for transparent and reproducible analyses to be
conducted. Case studies using this framework are
needed to demonstrate its use and identify any flaws.
Importantly, frameworks for systematic reviews should
be robust enough to adapt to future needs, and the
SYRINA framework was designed with this objective
in mind.
Endnotes
1DistillerSR® (https://distillercer.com/) is a proprietary
project management tool for tracking studies through
the screening process and storing data extracted from
these studies using user-customized forms.Rayyan is a
free web-based application (http://rayyan.qcri.org/) for
screening and storing information culled from studie-
s.Health Assessment Workspace Collaborative (HAWC):
A Modular Web-based Interface to Facilitate Develop-
ment of Human Health Assessments of Chemicals.
https://hawcproject.org/.
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